Fernández-Trujillo Sergio, Castañeda-Peñalvo Gregorio, Rodríguez-Flores Juana, Rodríguez Martín-Doimeadios Rosa Del Carmen
Department of Analytical Chemistry and Food Technology, Faculty of Chemical Sciences and Technologies, University of Castilla-La Mancha, Avenida de Camilo José Cela, 10, Ciudad Real, 13005, Spain.
Department of Analytical Chemistry and Food Technology, Faculty of Environmental Sciences and Biochemistry, University of Castilla-La Mancha, Avenida de Carlos III s/n, Toledo, 45071, Spain.
Anal Bioanal Chem. 2025 May 5. doi: 10.1007/s00216-025-05895-z.
The first nanotechnology-based innovative analytical strategy by means of dispersive solid-phase extraction (DSPE) as a necessary sample treatment approach for the simultaneous determination of revumenib and venetoclax in complex biological matrices such as human blood serum prior to high-performance liquid chromatography hyphenated to diode-array detector (HPLC-DAD) is reported. Several carbon nanotubes were rigorously evaluated as DSPE sorbents to obtain an adequate extraction and preconcentration of these chemotherapeutic agents. The best findings were 8 mg of pristine multi-walled carbon nanotubes (MWCNTs) in borate buffer (pH 10; 10 mM). Under optimized chromatographic conditions, the detection, identification, and determination of both anticancer agents and trazodone (internal standard) were done in less than 8 min of analysis. The HPLC-DAD separation was carried out in a C18 reversed-phase column with a mobile phase including ammonium acetate (pH 7; 10 mM) and methanol throughout a gradient elution mode with a sample flow rate of 0.9 mL min and a column temperature of 26°C. The preconcentration factor achieved was 1.7 so the limits of detection and quantification were 0.8 μg L and 2.6 μg L for revumenib and 0.7 μg L and 2.3 μg L for venetoclax in serum samples. The proposed strategy stands up as an interesting approach for therapeutic drug monitoring in AML patients moving away from a "one-size-fits-all" approach.
报道了第一种基于纳米技术的创新分析策略，即采用分散固相萃取（DSPE）作为必要的样品处理方法，用于在高效液相色谱-二极管阵列检测器（HPLC-DAD）联用之前，同时测定人血清等复杂生物基质中的瑞武尼布和维奈克拉。对几种碳纳米管作为DSPE吸附剂进行了严格评估，以实现这些化疗药物的充分萃取和预富集。最佳结果是在硼酸盐缓冲液（pH 10；10 mM）中使用8 mg原始多壁碳纳米管（MWCNT）。在优化的色谱条件下，两种抗癌药物和曲唑酮（内标）的检测、鉴定和测定在不到8分钟的分析时间内完成。HPLC-DAD分离在C18反相柱上进行，流动相包括醋酸铵（pH 7；10 mM）和甲醇，采用梯度洗脱模式，样品流速为0.9 mL/min，柱温为26°C。实现的预富集因子为1.7，因此血清样品中瑞武尼布的检测限和定量限分别为0.8 μg/L和2.6 μg/L，维奈克拉的检测限和定量限分别为0.7 μg/L和2.3 μg/L。所提出的策略是一种有趣的方法，可用于急性髓系白血病（AML）患者的治疗药物监测，摒弃了“一刀切”的方法。
